Budget Impact Analysis of Certolizumab Pegol in the Management of Patients With Moderate-To-Severe Active Rheumatoid Arthritis in Greece
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.2585
https://www.valueinhealthjournal.com/article/S1098-3015(14)04534-3/fulltext
Title :
Budget Impact Analysis of Certolizumab Pegol in the Management of Patients With Moderate-To-Severe Active Rheumatoid Arthritis in Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04534-3&doi=10.1016/j.jval.2014.08.2585
First page :
A375
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
287